IBEX insider trades: Dechant reports matched buy and sell totaling 45,027 shares

Rhea-AI Filing Summary

IBEX Ltd insider Robert Thomas Dechant reported same-day non-derivative transactions on 09/16/2025. He acquired 45,027 common shares at $19.00, bringing his beneficial ownership to 237,026 shares (direct), and sold 45,027 common shares at $38.89, leaving 191,999 shares (direct) after the transactions. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Insights

Securities Analyst

TL;DR: Insider executed equal-sized buy and sell on 09/16/2025, net effect reduced direct holdings to 191,999 shares.

The filing documents a matched acquisition and disposition of 45,027 common shares by CEO and director Robert T. Dechant. The acquisition was recorded at $19.00 per share (Code M) and the sale at $38.89 per share (Code S). Following these transactions his reported direct beneficial ownership is 191,999 shares. The form is routine Section 16 reporting of insider activity and contains no derivative transactions or additional explanatory remarks.

Corporate Governance Expert

TL;DR: Reporting person is both CEO and director; the Form 4 shows standard disclosure of same-day trades without extra commentary.

The report identifies Robert Thomas Dechant as a director and CEO. It discloses non-derivative purchases and sales executed on the same date resulting in a net decrease in his reported direct holdings to 191,999 shares. There are no indicated amendments, derivative positions, or explanatory remarks in the filing, and the signature was provided by an attorney-in-fact on 09/17/2025.

Insider Trade Summary

Net Seller: 45,027 shares ($1,751,100)

Net Sell 2 txns

Insider Dechant Robert Thomas

Role Chief Executive Officer

Sold 45,027 shs ($1.75M)

Type	Security	Shares	Price	Value
Exercise	Common Shares	45,027	$19.00	$856K
Sale	Common Shares	45,027	$38.89	$1.75M

Holdings After Transaction: Common Shares — 237,026 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dechant Robert Thomas

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/16/2025		M		45,027	A	$19	237,026	D
Common Shares	09/16/2025		S		45,027	D	$38.89	191,999	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did IBEX insider Robert T. Dechant report on Form 4?

He reported acquiring 45,027 common shares at $19.00 and selling 45,027 common shares at $38.89 on 09/16/2025.

What is Robert Dechant's reported ownership in IBEX after these trades?

The Form 4 reports 191,999 shares (direct) beneficially owned following the reported transactions.

What roles does the reporting person hold at IBEX?

The filing lists Robert Thomas Dechant as a Director and as an Officer (Chief Executive Officer).

Was the Form 4 signed and when?

The form was signed by an attorney-in-fact, Lisa Lenstrohm, on 09/17/2025.

Does the filing disclose any derivative securities or other remarks?

No. Table II for derivative securities contains no entries and there are no substantive remarks provided in the filing.